Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF-04937319

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Efficacy and safety of glucokinase activators for type 2 diabetes mellitus: A systematic review
Glucokinase activators (GKAs) are newly drug class proposed for diabetes treatment. This systematic review aimed to assess the… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 3
  • table 4
2019
2019
A novel Css-MRTpo approach to simulate oral plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite in humans using…
Abstract A Css-MRTpo superposition method was devised to predict (retrospectively) oral plasma concentration–time profiles of PF… Expand
2017
2017
Simulation of human plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi…
Abstract 1. The partial glucokinase activator N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy… Expand
2017
2017
Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus
Glucokinase is one of the promising targets for glucose-lowering agents, and the development of GK activators are now considered… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2016
2016
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF‐04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin—A Randomized, Crossover, Active…
Glucokinase enhances glucose conversion to glucose‐6‐phosphate, causing glucose‐stimulated insulin secretion from pancreatic… Expand
2015
2015
Two dose‐ranging studies with PF‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes
To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF‐04937319, as add‐on… Expand
2014
2014
The Relationship of Glucokinase Activator–induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies
Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2014
2014
Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator
The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl… Expand
  • table 1
  • table 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE